CA2246227A1 - Composition pour la transfection de cellules eucaryotes superieures - Google Patents

Composition pour la transfection de cellules eucaryotes superieures Download PDF

Info

Publication number
CA2246227A1
CA2246227A1 CA002246227A CA2246227A CA2246227A1 CA 2246227 A1 CA2246227 A1 CA 2246227A1 CA 002246227 A CA002246227 A CA 002246227A CA 2246227 A CA2246227 A CA 2246227A CA 2246227 A1 CA2246227 A1 CA 2246227A1
Authority
CA
Canada
Prior art keywords
egla
composition according
peptide
transfection
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002246227A
Other languages
English (en)
Inventor
Ernst Wagner
Karl Mechtler
Antoine Kichler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2246227A1 publication Critical patent/CA2246227A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une composition pour la transfection de cellules eucaryotes supérieures. Un complexe comprenant un acide nucléique à exprimer dans la cellule et un lipide cationique présent dans une concentration sous-optimale pour la transfection, contient un ou plusieurs peptides acides à action membranaire, ainsi qu'éventuellement un(des) lipide(s) auxiliaire(s). Le rapport du nombre total des charges positives au nombre total des charges négatives de la composition est compris entre approximativement 0 et approximativement 3.
CA002246227A 1996-02-15 1997-02-13 Composition pour la transfection de cellules eucaryotes superieures Abandoned CA2246227A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19605548A DE19605548A1 (de) 1996-02-15 1996-02-15 Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
DE19605548.2 1996-02-15

Publications (1)

Publication Number Publication Date
CA2246227A1 true CA2246227A1 (fr) 1997-08-21

Family

ID=7785445

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002246227A Abandoned CA2246227A1 (fr) 1996-02-15 1997-02-13 Composition pour la transfection de cellules eucaryotes superieures

Country Status (6)

Country Link
EP (1) EP0900281A1 (fr)
JP (1) JP2000504579A (fr)
CA (1) CA2246227A1 (fr)
DE (1) DE19605548A1 (fr)
MX (1) MX9805507A (fr)
WO (1) WO1997030170A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766705B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation
FR2766706B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
GB0120022D0 (en) * 2001-08-16 2001-10-10 Photobiotics Ltd Conjugate
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
WO2012006369A2 (fr) 2010-07-06 2012-01-12 Novartis Ag Immunisation de grands mammifères à l'aide de faibles doses d'arn
DK4066855T3 (da) 2010-08-31 2023-02-20 Glaxosmithkline Biologicals Sa Pegylerede liposomer til forsyning af RNA, der koder for immunogen
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
SG10201605537XA (en) 2011-07-06 2016-09-29 Novartis Ag Liposomes having useful n:p ratio for delivery of rna molecules
WO2013051718A1 (fr) 2011-10-07 2013-04-11 国立大学法人三重大学 Récepteur d'antigène chimérique
WO2017024319A1 (fr) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Dégradation modulable de protéine endogène
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN110121352B (zh) 2016-09-01 2020-12-11 嵌合体生物工程公司 Gold优化的car t-细胞
EP3580212A4 (fr) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. Régulation de récepteurs d'antigènes chimériques
EP3790896A1 (fr) 2018-05-07 2021-03-17 Children's Hospital Medical Center Polypeptides chimériques, molécules d'acide nucléique, cellules et procédés associés
CN114007643A (zh) 2019-04-19 2022-02-01 中外制药株式会社 识别抗体改变部位的嵌合受体
MX2021014433A (es) 2019-06-05 2022-03-11 Chugai Pharmaceutical Co Ltd Molecula de union a sitio de escision de anticuerpo.
JPWO2022025220A1 (fr) 2020-07-31 2022-02-03
TW202300522A (zh) 2021-03-17 2023-01-01 日商第一三共股份有限公司 編碼對抗乙醯膽鹼受體自體抗體之嵌合受體之基因
WO2022214887A1 (fr) 2021-04-08 2022-10-13 Phosphogam, Llc Procédés et compositions d'amélioration de la cytotoxicité des lymphocytes t gamma/delta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
FR2714830B1 (fr) * 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
JP4338106B2 (ja) * 1995-06-07 2009-10-07 ライフ テクノロジーズ コーポレーション ペプチド増強カチオン脂質トランスフェクション
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition

Also Published As

Publication number Publication date
JP2000504579A (ja) 2000-04-18
DE19605548A1 (de) 1997-09-04
MX9805507A (es) 1998-11-29
WO1997030170A1 (fr) 1997-08-21
EP0900281A1 (fr) 1999-03-10

Similar Documents

Publication Publication Date Title
CA2246227A1 (fr) Composition pour la transfection de cellules eucaryotes superieures
AU747803B2 (en) Novel compositions for the delivery of negatively charged molecules
US8058068B2 (en) Peptide-enhanced transfections
US7772201B2 (en) Highly branched HK peptides as effective carriers of siRNA
Martin et al. Peptide-guided gene delivery
JP4265699B2 (ja) ペプチドによって増強されるトランスフェクション
ES2200051T3 (es) Metodos y composiciones para la lipidizacion de moleculas hidrofilas.
US7553830B2 (en) Compositions for the delivery of negatively charged molecules
SK281543B6 (sk) Farmaceutická kompozícia na transfekciu nukleovej kyseliny
US20030165567A1 (en) Histidine copolymer and methods for using same
JPH11506935A (ja) ペプチド増強カチオン脂質トランスフェクション
SK282173B6 (sk) Lipopolyamíny ako transfekčné činidlá, spôsob ich prípravy a farmaceutické kompozície s ich obsahom
RU2739987C2 (ru) Множественные олигонуклеотидные фрагменты на пептидном носителе
US9399016B2 (en) Materials and complexes for the delivery of biologically-active materials to cells
US6281371B1 (en) Lipopolyamines, and the preparation and use thereof
AU720697B2 (en) Pharmaceutical composition which is useful for the transfection of nucleic acids, and uses thereof
JP2019510083A (ja) 生物学的活性物質の細胞への送達のための脂質および複合体
Maslov et al. Cationic amphiphiles of both lipid and nonlipid nature in gene therapy
WO1999065461A3 (fr) Complexes micellaires d'amphiphiles cationiques
US7297712B2 (en) Cationic amphiphiles for intracellular delivery of therapeutic molecules and its composition, process and method of treatment
Chaum et al. LIPID MEDIATED GENE TRANSFER LIPID MEDIATED GENE TRANSFER
EP1724254A2 (fr) Nouvelles compositions d'administration de molecules chargées negativement
KR20180010235A (ko) 생물학적으로 절단가능한 테트라펩티드 연결제
MXPA97006016A (en) Composition containing nucleic acids, preparation and use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead